Sexually transmitted disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 19 Jun 2026 04:03:25 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Sexually transmitted disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 A study to compare weekly or event-based use of doxycycline to prevent sexually transmitted infections in men who have sex with men and transgender women using HIV prevention medication. https://clinicaltrials.eu/trial/a-study-to-compare-weekly-or-event-based-use-of-doxycycline-to-prevent-sexually-transmitted-infections-in-men-who-have-sex-with-men-and-transgender-women-using-hiv-prevention-medication/ Wed, 29 Apr 2026 15:09:19 +0000 https://clinicaltrials.eu/trial/a-study-to-compare-weekly-or-event-based-use-of-doxycycline-to-prevent-sexually-transmitted-infections-in-men-who-have-sex-with-men-and-transgender-women-using-hiv-prevention-medication/ This study focuses on the prevention of Sexually Transmitted Infections, which are infections passed from one person to another through sexual contact. Specifically, the research looks at Neisseria gonorrhoeae, which causes gonorrhea, Chlamydia trachomatis, which causes chlamydia, and Treponema pallidum, the bacteria that causes syphilis. The study involves individuals who are already using PrEP, a medication taken to prevent HIV infection.

The purpose of the study is to compare two different ways of using doxycycline to prevent these infections after potential exposure. One method involves taking the medication every week, while the other method involves taking the medication only after specific events occur. Participants will be assigned to one of these two groups to see which schedule is more effective at reducing the number of new infections.

]]> Study on the Effects of Doxycycline for Preventing Antibiotic Resistance in Patients with Bacterial STDs (Chlamydia, Gonorrhea, Syphilis) https://clinicaltrials.eu/trial/study-on-the-effects-of-doxycycline-for-preventing-antibiotic-resistance-in-patients-with-bacterial-stds-chlamydia-gonorrhea-syphilis/ Wed, 29 Apr 2026 15:05:29 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-doxycycline-for-preventing-antibiotic-resistance-in-patients-with-bacterial-stds-chlamydia-gonorrhea-syphilis/ This clinical trial is focused on studying the effects of a medication called doxycycline on certain bacterial infections that are sexually transmitted, such as chlamydia, gonorrhea, and syphilis. The study will use a form of doxycycline known as Doxycycline EG 200 mg Tabletten, which is taken orally as a tablet. The purpose of the study is to see if taking doxycycline after being exposed to these infections can affect how bacteria in the body respond to the medication over time.

Participants in the study will take doxycycline as a preventive measure after potential exposure to these infections. The study will monitor changes in the bacteria found in the body, particularly in the intestines, to see if they become less sensitive to doxycycline. This is important because it helps understand if the bacteria are developing resistance to the medication, which could make it less effective in the future.

The study will last for several months, with participants being observed for changes in the bacteria at different points, including at the start and after 180 days. The researchers will also look at how other bacteria, such as E. coli and K. pneumoniae, respond to doxycycline and other antibiotics like ceftriaxone and ciprofloxacin. This information will help determine the impact of using doxycycline as a preventive treatment on the overall resistance of bacteria to antibiotics.

]]> Study on Doxycycline for Reducing Bacterial STIs in MSM and TGW with HIV https://clinicaltrials.eu/trial/study-on-doxycycline-for-reducing-bacterial-stis-in-msm-and-tgw-with-hiv/ Wed, 29 Apr 2026 15:05:06 +0000 https://clinicaltrials.eu/trial/study-on-doxycycline-for-reducing-bacterial-stis-in-msm-and-tgw-with-hiv/ This clinical trial is focused on studying the effectiveness of a treatment called doxyPEP in reducing the occurrence of certain bacterial sexually transmitted infections (STIs) among men who have sex with men (MSM) and transgender women (TGW) living with HIV in Belgium. The bacterial STIs being studied include infections caused by Neisseria gonorrhoeae, Chlamydia trachomatis, and Treponema pallidum. The treatment involves the use of a medication called Doxycycline, which is a type of antibiotic. Participants in the study will receive either the doxyPEP treatment or a placebo.

The purpose of the study is to determine if doxyPEP can effectively reduce the rate of these bacterial infections compared to a placebo. The study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure the results are unbiased. Participants will be randomly assigned to either the doxyPEP group or the placebo group and will switch between the two during the study period, which is known as a cross-over design.

Throughout the study, participants will be monitored for any symptoms of the bacterial STIs being studied. The trial will also look at other factors, such as the presence of resistance genes and changes in the natural bacteria found in the body. The study is expected to continue until 2027, with recruitment starting in 2025. This research aims to provide valuable insights into the potential benefits of using doxyPEP as a preventive measure for bacterial STIs in individuals living with HIV.

]]>